Earnings call Recursion Pharmaceuticals delivered strong operational progress with a 30% YoY reduction in operating expenses and an extended cash runway into early 2028. Clinical momentum was ...
Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results